Visceral Pain Treatment Market Size by Drug Type, Indication, Distribution Channel, Application, Region – Revenue Pool Analysis, Margin Structure Assessment, Capital Flow Trends, Competitive Benchmarking & Forecast to 2030
Overview
The Visceral Pain Treatment Market size was valued at USD 14.34 Billion in 2023 and the total Visceral Pain Treatment revenue is expected to grow at a CAGR of 5.3% from 2024 to 2030, reaching nearly USD 20.58 Billion.
The global Visceral Pain Treatment market report is a comprehensive analysis of the industry, market, and key players. The report has covered the market by demand and supply-side by segments. The global Visceral Pain Treatment report also provides trends by market segments, technology, and investment with a competitive landscape.
Visceral Pain Treatment Market Overview:
Visceral pain can be caused by injuries to organs such as the gallbladder, intestines, bladder, or kidneys. This causes visceral pain that ranges from severe, persistent, to very deep discomfort that feels like it's squeezing out of the body. Medications including painkillers, spasmolytics, and antidepressants are used for symptomatic therapy.
To know about the Research Methodology :- Request Free Sample Report
Global Visceral Pain Treatment Market Dynamics:
Drivers:
Over the forecast period, increased awareness of visceral pain and the increasing prevalence of the condition is expected to fuel market growth.
To create novel therapeutics in the visceral pain treatment market, key companies in the market are heavily spending on research and development and conducting clinical studies. During the projected period, medication approvals are expected to considerably fuel market expansion and generate attractive potential possibilities in the visceral pain treatment market.
In addition, the increased prevalence of irritable bowel syndrome (IBS) over the world is expected to fuel market expansion. In the United States, around 70,000 new cases of IBD are identified each year. During the years 2003–2013, the hospitalization rate of secondary diagnosed IBD patients grew dramatically, rising from 44.2 to 59.7 per 100,000 people.
Irritable bowel syndrome (IBS), which is becoming more common, is likely to boost market development. Irritable bowel syndrome affects between 10% and 15% of individuals worldwide each year, according to the IFFBD (International Foundation for Gastrointestinal Disorders).
Shortly, the recent introduction and approval of new medications in North America, Europe, and Japan are expected to increase demand for visceral pain therapy. MEDI2070 interleukin-23 monoclonal antibody is being developed by AstraZeneca and Allergan to treat ulcerative colitis and Crohn's disease. The MEDI2070 is now being tested in phase IIb clinical trial for moderate to severe Crohn's disease and clinical trial phase II for ulcerative colitis PF-00547659 by Pfizer and Ozanimod by Celgene are in phase II and phase III clinical trials, respectively, for Crohn's disease and ulcerative colitis.
Restraints:
However, a key issue that is predicted to stymie the growth of the visceral pain treatment market is the absence of particular therapy for visceral pain conditions such as irritable bowel syndrome and Crohn's disease. Furthermore, rivalry among leading industry players for the discovery of innovative medications for visceral pain is predicted to be a major factor limiting the market's expansion.
Furthermore, throughout the projected period, the high cost of medications, and patent expiration of leading pharmaceuticals are likely to be a key impediment to the growth of the visceral pain treatment market.
Global Visceral Pain Treatment Market Segment Analysis:
Based on Drug Type, the analgesics category dominated the market, in 2023. Non-opioid analgesics are the first-line therapy for visceral pain. Aleve (naproxen) and aspirin are two over-the-counter non-steroidal anti-inflammatories (NSAIDs) analgesics that are commonly used to relieve visceral discomfort (acetylsalicylic acid).
Under the firms' previously announced interim exclusive supply and distribution agreement, the FDA approved Levothyroxine Sodium Tablets USP, an opioid pain medication. Baudax Bio was founded as a new pharmaceutical firm to develop non-opioid analgesic medicines that are both effective and safe.
Based on Indication, the ulcerative colitis segment held the highest market share, followed by the Crohn's disease segment. Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), is a chronic inflammatory condition with an unknown cause.
In the recent several decades, there has been a significant increase in the frequency and incidence of IBDs, which is expected to continue over the projection period. According to IBD Support Australia Incorporated, inflammatory bowel disease affects roughly 61,000 people in Australia, with Crohn's disease affecting 28,000 individuals and ulcerative colitis affecting 33,000.
Based on Distribution Channel, the retail pharmacies segment held a large part of the market in 2023, and this trend is likely to continue during the projected period, in terms of revenue.
Due to favorable demographic circumstances and an epidemiological change, the retail pharmacy industry has seen tremendous development in recent years. The segment is expected to grow due to the inclusion of many drugs within the OTC category and a preference for self-medication.
Regional Insights:
North America dominated the visceral pain treatment market in 2023 and is expected to continue dominating the industry over the forecast period. This dominance is largely due to pharmaceutical firms' increased attention on R&D and cooperative partnerships to create new medications for visceral pain.
In addition, the increased prevalence of irritable bowel syndrome and Crohn's disease is expected to drive regional market expansion throughout the projection period. Irritable bowel disease (IBD), such as ulcerative colitis or Crohn's disease, was diagnosed in roughly 3 million persons in 2015, according to the Centers for Disease Control and Prevention (CDC).
Furthermore, due to increased expenditures by pharma firms and government programs for visceral pain treatment, the Asia Pacific region is expected to develop at the quickest rate throughout the projection period. In the Asia Pacific area, firms including Glenmark Pharmaceuticals, Takeda Pharmaceutical Company, and others sell visceral pain medications and treatments.
Additionally, government agencies such as the Australian government are working to raise knowledge of visceral discomfort and how to treat it.
The objective of the report is to present a comprehensive analysis of the global Visceral Pain Treatment market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding the global Visceral Pain Treatment market dynamics, structure by analyzing the market segments and project the global Visceral Pain Treatment market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global Visceral Pain Treatment market make the report investor’s guide.
Global Visceral Pain Treatment Market Key Developments:
In August 2021, under the terms of a recently announced interim exclusive supply and distribution agreement, Lannett Company, Inc. has launched Cediprof, Inc.'s FDA-approved Levothyroxine Sodium Tablets USP, an opioid pain reliever.
In February 2021, The Drugs for Neglected Diseases Initiative (DNDi) and Novartis have agreed to work together to develop ‘LXE408' as a potential new therapy for visceral leishmaniasis, which is one of the world's major parasite killers. LXE408, a first-in-class chemical, was discovered with financial assistance from Novartis' Welcome Trust.
In January 2021, Ironwood Pharmaceuticals Inc., a biotechnology company based in the United States, announced that the National Medical Products Administration has approved the marketing applications of LINZESS® (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) in China and that the launch will take place in the second half of 2021 with its Chinese partner, AstraZeneca.
Global Visceral Pain Treatment Market Scope: Inquire before buying
| Global Visceral Pain Treatment Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2023 | Forecast Period: | 2024-2030 |
| Historical Data: | 2018 to 2023 | Market Size in 2023: | USD 14.34 Bn. |
| Forecast Period 2024 to 2030 CAGR: | 5.3% | Market Size in 2030: | USD 20.58 Bn. |
| Segments Covered: | by Drug Type | Analgesics Narcotics NSAID Pain Modifiers Tricyclic Antidepressants Tricyclic Anticonvulsant Others |
|
| by Indication | Interstitial Cystitis Crohn’s Irritable Bowel Chronic Prostatitis |
||
| by Distribution Channel | Hospital Pharmacy Online Pharmacy Retail Pharmacy |
||
| by Application | In-patient Out-patient |
||
Visceral Pain Treatment Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Global Visceral Pain Treatment Market, Key Players
1. Addex Therapeutics Ltd
2. AstraZeneca
3. Astellas Pharma Inc.
4. Neurim Pharmaceuticals Ltd.
5. Abbvie
6. Pfizer Inc
7. Glcare Pharma Inc
8. Chromocell Corporation
9. Allergan Inc
10.Johnson & Johnson Services Inc
11.Grunenthal GmbH
12.Takeda Pharmaceutical Company Limited
13.Medestea Research & Production S.p.A
14.Novartis AG
15.Sanofi
16.GlaxoSmithKline plc
17.Glenmark Pharmaceuticals
18.Other Key Players
Frequently Asked Questions:
1. Which region has the largest share in Global Visceral Pain Treatment Market?
Ans: North America region held the highest share in 2023.
2. What was the Global Visceral Pain Treatment Market size in 2023?
Ans: The Global Visceral Pain Treatment Market size was USD 14.34 Billion in 2023.
3. What is scope of the Global Visceral Pain Treatment Market report?
Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Visceral Pain Treatment Market?
Ans: The important key players in the Global market are – Addex Therapeutics Ltd, AstraZeneca, Astellas Pharma Inc., Neurim Pharmaceuticals Ltd., Abbvie, Pfizer Inc, Glcare Pharma Inc, Chromocell Corporation, Allergan Inc, Johnson & Johnson Services Inc, Grunenthal GmbH, Takeda Pharmaceutical Company Limited, Medestea Research & Production S.p.A, Novartis AG, Sanofi, GlaxoSmithKline plc, Glenmark Pharmaceuticals, and Other Key Players.
5. What is the study period of this Market?
Ans: The Global Visceral Pain Treatment Market is studied from 2023 to 2030.